<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24736" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>MAO Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sabri</surname>
            <given-names>Mohamed A.</given-names>
          </name>
          <aff>University of Sharjah</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saber-Ayad</surname>
            <given-names>Maha M.</given-names>
          </name>
          <aff>College of Medicine, University of Sharjah</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohamed Sabri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maha Saber-Ayad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24736.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Monoamine oxidase inhibitors (MAO Inhibitors) are medications used to manage and treat depression, among other neurological and psychiatric illnesses. It is in the Antidepressants class of drugs. This activity reviews the indications, action, and contraindications of the commonly prescribed MAO Inhibitors as a valuable agent in managing depression and other neuropsychiatric disorders. This activity will highlight the mechanism of action, adverse event profile, and other key factors such as off-label use, administration, and relevant molecular interactions pertinent for the interprofessional team members involved in the care of patients with depression and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the mechanism of action of MAOIs.</p></list-item><list-item><p>Identify the indications for prescribing MAOIs in clinical practice.</p></list-item><list-item><p>Summarize the contraindications and potential side effects associated with MAOIs.</p></list-item><list-item><p>Outline the importance of effective communication amongst the healthcare team members in delivering quality, complication-free management to the patients under their care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24736&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24736">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24736.s2" sec-type="Indications">
        <title>Indications</title>
        <p>In the 1950s, monoamine oxidase inhibitors (MAOIs) were&#x000a0;among the first drugs to be utilized as antidepressants in clinical practice.<xref ref-type="bibr" rid="article-24736.r1">[1]</xref> To this day, the available literature shows that MAOIs remain a useful and efficacious tool in treating atypical depression, panic, social anxiety disorders, treatment-resistant depression, and, to some extent, bipolar disorder.<xref ref-type="bibr" rid="article-24736.r2">[2]</xref><xref ref-type="bibr" rid="article-24736.r3">[3]</xref> Four MAOIs are FDA approved to treat depression in the US; these are isocarboxazid, phenelzine, tranylcypromine, and selegiline.</p>
        <p>That said, due to their broad adverse effect profile and multiple drug-drug and drug-food interactions, MAOIs are not first or second-line drugs in the management of depression.<xref ref-type="bibr" rid="article-24736.r4">[4]</xref><xref ref-type="bibr" rid="article-24736.r5">[5]</xref> Nevertheless, in cases of treatment-resistant unipolar depression, a double-blind crossover study of imipramine and phenelzine found that response to treatment occurred more frequently in patients switched to phenelzine than those switched to imipramine.<xref ref-type="bibr" rid="article-24736.r6">[6]</xref> Additionally, there is a preferential response to MAOIs in patients diagnosed with atypical depression (a subtype of depression featuring a pattern of mood reactivity, hypersomnia, increased appetite or weight gain, leaden paralysis, and interpersonal rejection sensitivity.)<xref ref-type="bibr" rid="article-24736.r7">[7]</xref></p>
        <p>In addition to the indications mentioned above, selective MAO-B inhibitors (MAOBIs) have shown some effectiveness in the symptomatic treatment of mild Parkinson disease (PD) early in its course. Patients with early PD symptoms given MAOBIs show reductions in motor symptoms and a lower need for levodopa without a substantial increase in morbidity or mortality.<xref ref-type="bibr" rid="article-24736.r8">[8]</xref> These therapeutic effects occur whether patients are given MAOBIs as an adjunctive treatment with levodopa or as monotherapy.<xref ref-type="bibr" rid="article-24736.r9">[9]</xref></p>
      </sec>
      <sec id="article-24736.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Monoamine oxidases function as catalysts for the oxidative deamination of monoamines, including the neurotransmitters serotonin and histamine, as well as the catecholamines dopamine, norepinephrine, and epinephrine. There are two main isoenzymes of monoamine oxidases: MAO-A and MAO-B. Norepinephrine, epinephrine, dopamine, tryptamine, and tyramine are all oxidized by both isoenzymes. On the other hand, serotonin is mainly oxidized by MAO-A.<xref ref-type="bibr" rid="article-24736.r10">[10]</xref></p>
        <p>MAOs are present in most of our body&#x02019;s tissues, but their distribution is not even. In the brain, most of the MAOs are present in the striatum of the basal ganglia and the hypothalamus.<xref ref-type="bibr" rid="article-24736.r11">[11]</xref> The main form being MAO-B in the basal ganglia. However, in the intestines, MAO-B is only found in trace amounts, leaving MAO-A the dominant of both isoenzymes.</p>
        <p>Inhibitors of monoamine oxidases function, as the name implies, by inhibiting the enzyme MAO, and thus result in the accumulation of its substrates (the monoamine and catecholamine neurotransmitters, as well as tyramine ingested in some foods.) The accumulation of serotonin, norepinephrine and dopamine in the synaptic clefts in the CNS is then responsible for MAOIs&#x02019; antidepressant effect. It&#x02019;s important to state that this is mainly dependent on the inhibition of MAO-A, with MAO-B inhibitors being devoid of antidepressant activity. This effect is likely due to the heterogenicity of isoenzyme distribution in the brain. Conversely, the motor symptom alleviation effects of MAOIs are mainly achievable via the selective inhibition of MAO-B (as this is the dominant isoenzyme in the basal ganglia). <italic toggle="yes">L</italic>-deprenyl (selegiline), being one of the selective MAO-B inhibitors (at low doses), is effective in treating early Parkinson disease symptoms.<xref ref-type="bibr" rid="article-24736.r12">[12]</xref></p>
      </sec>
      <sec id="article-24736.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The four most commonly prescribed MAOIs are selegiline, isocarboxazid, phenelzine, and tranylcypromine. Their administration is discussed below:</p>
        <p>Selegiline&#x02019;s now preferred method of administration is through a transdermal patch. The drug&#x02019;s extensive &#x0201c;first pass&#x0201d; metabolism through the liver results in a low bioavailability when taken orally; this necessitates the administration of a relatively large oral dose which predisposes patients for the &#x0201c;cheese reaction&#x0201d; side effect of MAOIs (discussed later) through the inhibition of MAO-A in the intestines. The transdermal patch avoids the &#x0201c;first pass&#x0201d; metabolism, eliminating the need for a large bolus dose and decreasing the chances of developing the &#x0201c;cheese reaction&#x0201d; side effect.<xref ref-type="bibr" rid="article-24736.r13">[13]</xref><xref ref-type="bibr" rid="article-24736.r14">[14]</xref> In fact, dietary restrictions are not necessary when using the 6 mg/24-hour patch.&#x000a0; Selegiline is also available in tablet form. Isocarboxazid, phenelzine, and tranylcypromine, on the other hand, are only available in oral tablet form.</p>
        <p>As with other antidepressants, MAOIs require few weeks; usually, 4 weeks, before a clinically apparent response. Also, certain considerations are necessary when switching antidepressants to and from MAOIs. The current antidepressant dose should be tapered off over 2 to 4 weeks then completely discontinued before switching to another antidepressant. Next, two weeks should elapse from the last dose of antidepressant and the first dose of an MAOI. A five-week gap should be allowed for fluoxetine, especially due to its relatively long half-life.<xref ref-type="bibr" rid="article-24736.r15">[15]</xref> Similarly, two weeks are necessary when switching from an MAOI after tapering it off to allow for MAO enzyme reconstitution by the cells.</p>
      </sec>
      <sec id="article-24736.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>MAOIs have a potent hypotensive effect, leading to almost half of their users experiencing dizziness.; this is an important adverse effect to watch for, especially in elderly patients.<xref ref-type="bibr" rid="article-24736.r16">[16]</xref><xref ref-type="bibr" rid="article-24736.r17">[17]</xref><xref ref-type="bibr" rid="article-24736.r18">[18]</xref></p>
        <p>A significant and potentially fatal side effect of MAOIs is the hypertensive crisis or the &#x0201c;cheese reaction.&#x0201d; This adverse event occurs when taking MAOIs along with sympathomimetic amines such as tyramine found in some fermented foods like cheese.<xref ref-type="bibr" rid="article-24736.r19">[19]</xref> It is important to note that selective MAO-B inhibitors do not have such an adverse effect, as the intestines contain very little MAO-B.<xref ref-type="bibr" rid="article-24736.r20">[20]</xref> Another point worth mentioning is that the development of reversible, selective MAO-A inhibitors also avoided this issue. MAO-A inhibitors can successfully block enough MAO-A in the brain while having a low enough affinity to allow its displacement by dietary tyramine from intestinal MAO-A.<xref ref-type="bibr" rid="article-24736.r21">[21]</xref></p>
        <p>Serotonin syndrome, or serotonin toxicity, is another potentially life-threatening condition that can be precipitated by co-administration of MAOIs with other antidepressants or serotonergic agents. Clinical features include mental status changes such as delirium, autonomic manifestations such as tachycardia, hypertension, diarrhea, and neuromuscular hyperactivity, manifesting as tremors and hyperreflexia.<xref ref-type="bibr" rid="article-24736.r22">[22]</xref><xref ref-type="bibr" rid="article-24736.r23">[23]</xref></p>
        <p>Also, abrupt cessation of MAOIs can result in antidepressant discontinuation syndrome; symptoms may include anxiety, agitation, insomnia, chills, diaphoresis, headache, irritability, malaise, and nausea.<xref ref-type="bibr" rid="article-24736.r24">[24]</xref><xref ref-type="bibr" rid="article-24736.r25">[25]</xref> Other common side effects include sexual dysfunction, insomnia, headaches, and weight gain. Many antidepressants share these traits.</p>
      </sec>
      <sec id="article-24736.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>As previously stated, prescribing MAOIs with any sympathomimetic agent may precipitate a hypertensive crisis. For that reason, it is contraindicated to co-administer these agents. Moreover, preparations containing ephedrine, phenylephrine, phenylpropanolamine, or pseudoephedrine such as cold and nasal decongestion remedies should not be given concomitantly with MAOIs for the same reason. Similarly, levodopa should be utilized with caution in patients on MAOIs as it increases the levels of circulating noradrenaline.<xref ref-type="bibr" rid="article-24736.r26">[26]</xref> Sublingual nifedipine is also absolutely contraindicated for the treatment of hypertension if the patient is on an MAOI.<xref ref-type="bibr" rid="article-24736.r27">[27]</xref> One should also be wary of any signs and symptoms of pheochromocytoma or other catecholamine-releasing paragangliomas since giving MAOIs to patients suffering from these conditions will most likely trigger a hypertensive crisis.</p>
        <p>Serotonergic antidepressants cotemporally administered with MAOIs increase the chances of serotonin syndrome precipitation, so it is generally advised against the co-prescription of those agents. If utilized in cases of treatment-resistant depression, rigorous monitoring is necessary.<xref ref-type="bibr" rid="article-24736.r26">[26]</xref></p>
        <p>For the sake of avoiding a hypertensive crisis, or the so-called &#x0201c;pressor response&#x0201d; of tyramine found in some foods, dietary restrictions require implementation. Classically, all aged cheeses are absolutely contraindicated, as well as all aged, smoked, pickled, or cured meats, fish, and poultry. A variety of other foods, including over-ripened fruit, are also contraindicated.<xref ref-type="bibr" rid="article-24736.r26">[26]</xref> That said, reviews from food science literature on tyramine concentrations in food revealed that tyramine concentrations in modern food are less than ever and that this trend is continuing. The conclusion is that in the right portions, all foods may be allowed in the MAOI diet.<xref ref-type="bibr" rid="article-24736.r28">[28]</xref></p>
        <p>It also goes without saying that patients&#x02019; refusal to take the medication or severe allergy to MAOIs are absolute contraindications to their administration.</p>
      </sec>
      <sec id="article-24736.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>It is essential to evaluate the mood and mental status of adolescent recipients of MAOIs, as with any other antidepressant; these medications may increase the risk for suicide in those aged 18 to 24 years.<xref ref-type="bibr" rid="article-24736.r29">[29]</xref></p>
        <p>Baseline and periodic monitoring of renal and hepatic functions and blood pressure measurements should be taken for those on MAOIs. Blood glucose also requires monitoring, as noradrenergic effects of MAOIs lead to a decrease in insulin production and an increase in glucagon secretion.<xref ref-type="bibr" rid="article-24736.r30">[30]</xref> This is of particular concern in diabetic patients.</p>
        <p>For those on MAO-B inhibitors such as selegiline, periodic evaluation for parkinsonism is advisable.</p>
      </sec>
      <sec id="article-24736.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no specific antidote for MAOI toxicity, and dialysis is unhelpful in removing the drug. An overdose of MAOIs, or use in combination with other serotonergic agents, may lead to serotonin toxicity. Likewise, the use of MAOIs with sympathomimetic agents may lead to the development of a hypertensive crisis.</p>
        <p>When managing serotonin syndrome, early transfer to a medical ICU and consultation with a toxicologist is strongly advised. Diagnosis of serotonin toxicity is possible using the &#x0201c;Hunter criteria&#x0201d; or the &#x0201c;Sternbach criteria&#x0201d; based on physical manifestations.<xref ref-type="bibr" rid="article-24736.r22">[22]</xref> The mainstay of management is the discontinuation of the serotonergic agent and supportive care, where most patients improve within 24 hours.<xref ref-type="bibr" rid="article-24736.r31">[31]</xref></p>
        <p>In cases of hypertensive crisis, immediate admission to the ICU for prompt blood pressure control with a parenteral, titratable antihypertensive agent while the patient remains on a vitals monitor is necessary. Urine output measurements and a neurologic examination should also take place. BP correction should be slowly achieved over several minutes to an hour, and not immediately. The goal is to lower the BP to no less than 20% to 25% during the first hour.<xref ref-type="bibr" rid="article-24736.r32">[32]</xref></p>
      </sec>
      <sec id="article-24736.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients requiring MAOI administration often are refractory to other medications and require an interprofessional team of healthcare professionals, including a nurse, laboratory technologists, pharmacists, and several physicians in different specialties. Without proper monitoring, there is a risk of developing potentially fatal adverse effects such as serotonin syndrome or a hypertensive crisis.</p>
        <p>An MAOI prescription will require the patient to follow up with a dietitian to ensure a safe diet that does not trigger a food-drug interaction with the medication. Moreover, patients who have Parkinson disease may be put on an MAOI as part of early management by a neurologist. PD patients often develop depressive episodes as the disease progresses and may benefit from follow-up with a psychiatrist.</p>
        <p>Only by working as an interprofessional team can we reduce the likelihood of and monitor potential side effects of MAOIs. Data available from published literature shows that the use of rasagiline improves motor fluctuations and PD symptoms in early course Parkinson&#x02019;s disease patients on levodopa.<xref ref-type="bibr" rid="article-24736.r12">[12]</xref>&#x000a0;[Level 1] Furthermore, research also shows that treatment with the MAOI phenelzine is more effective in alleviating symptoms in chronically ill patients of major depressive disorder in contrast to treatment with the TCA imipramine.<xref ref-type="bibr" rid="article-24736.r6">[6]</xref>&#x000a0;[Level 2]</p>
      </sec>
      <sec id="article-24736.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24736&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24736">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24736/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24736">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24736.s11">
        <title>References</title>
        <ref id="article-24736.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez-Mu&#x000f1;oz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alamo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today.</article-title>
            <source>Curr Pharm Des</source>
            <year>2009</year>
            <volume>15</volume>
            <issue>14</issue>
            <fpage>1563</fpage>
            <page-range>1563-86</page-range>
            <pub-id pub-id-type="pmid">19442174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menkes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bosanac</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Castle</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>MAOIs - does the evidence warrant their resurrection?</article-title>
            <source>Australas Psychiatry</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>371</fpage>
            <page-range>371-3</page-range>
            <pub-id pub-id-type="pmid">26917855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ipser</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Balkom</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for social phobia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2004</year>
            <month>Oct</month>
            <day>18</day>
            <issue>4</issue>
            <fpage>CD001206</fpage>
            <pub-id pub-id-type="pmid">15495010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014.</article-title>
            <source>Am J Psychiatry</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>174</volume>
            <issue>5</issue>
            <fpage>438</fpage>
            <page-range>438-450</page-range>
            <pub-id pub-id-type="pmid">28135844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thase</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>The role of monoamine oxidase inhibitors in depression treatment guidelines.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2012</year>
            <volume>73 Suppl 1</volume>
            <fpage>10</fpage>
            <page-range>10-6</page-range>
            <pub-id pub-id-type="pmid">22951237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGrath</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Ocepek-Welikson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rabkin</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Quitkin</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression.</article-title>
            <source>Am J Psychiatry</source>
            <year>1993</year>
            <month>Jan</month>
            <volume>150</volume>
            <issue>1</issue>
            <fpage>118</fpage>
            <page-range>118-23</page-range>
            <pub-id pub-id-type="pmid">8417553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaynes</surname>
                <given-names>BN</given-names>
              </name>
            </person-group>
            <article-title>Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2009</year>
            <volume>70 Suppl 6</volume>
            <fpage>10</fpage>
            <page-range>10-5</page-range>
            <pub-id pub-id-type="pmid">19922739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ives</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Stowe</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Marro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Counsell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Macleod</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.</article-title>
            <source>BMJ</source>
            <year>2004</year>
            <month>Sep</month>
            <day>11</day>
            <volume>329</volume>
            <issue>7466</issue>
            <fpage>593</fpage>
            <pub-id pub-id-type="pmid">15310558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <collab>Parkinson Study Group</collab>
            <article-title>A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.</article-title>
            <source>Arch Neurol</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>59</volume>
            <issue>12</issue>
            <fpage>1937</fpage>
            <page-range>1937-43</page-range>
            <pub-id pub-id-type="pmid">12470183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Youdim</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Edmondson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tipton</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>The therapeutic potential of monoamine oxidase inhibitors.</article-title>
            <source>Nat Rev Neurosci</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-309</page-range>
            <pub-id pub-id-type="pmid">16552415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Carroll</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Tobbia</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tipton</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.</article-title>
            <source>Naunyn Schmiedebergs Arch Pharmacol</source>
            <year>1983</year>
            <month>Apr</month>
            <volume>322</volume>
            <issue>3</issue>
            <fpage>198</fpage>
            <page-range>198-202</page-range>
            <pub-id pub-id-type="pmid">6408492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <collab>Parkinson Study Group</collab>
            <article-title>A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.</article-title>
            <source>Arch Neurol</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>241</fpage>
            <page-range>241-8</page-range>
            <pub-id pub-id-type="pmid">15710852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanDenBerg</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>The transdermal delivery system of monoamine oxidase inhibitors.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2012</year>
            <volume>73 Suppl 1</volume>
            <fpage>25</fpage>
            <page-range>25-30</page-range>
            <pub-id pub-id-type="pmid">22951239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azzaro</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ziemniak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kemper</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>VanDenBerg</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>10</issue>
            <fpage>1256</fpage>
            <page-range>1256-67</page-range>
            <pub-id pub-id-type="pmid">17715422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ogle</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Akkerman</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Guidance for the discontinuation or switching of antidepressant therapies in adults.</article-title>
            <source>J Pharm Pract</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>389</fpage>
            <page-range>389-96</page-range>
            <pub-id pub-id-type="pmid">23459282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Quitkin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tricamo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>270</fpage>
            <page-range>270-8</page-range>
            <pub-id pub-id-type="pmid">6386898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabkin</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Quitkin</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tricamo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>1985</year>
            <month>Feb</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-9</page-range>
            <pub-id pub-id-type="pmid">3973068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volz</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Gleiter</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Monoamine oxidase inhibitors. A perspective on their use in the elderly.</article-title>
            <source>Drugs Aging</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>341</fpage>
            <page-range>341-55</page-range>
            <pub-id pub-id-type="pmid">9829163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Da Prada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Z&#x000fc;rcher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>W&#x000fc;thrich</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Haefely</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.</article-title>
            <source>J Neural Transm Suppl</source>
            <year>1988</year>
            <volume>26</volume>
            <fpage>31</fpage>
            <page-range>31-56</page-range>
            <pub-id pub-id-type="pmid">3283290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Youdim</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Weinstock</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.</article-title>
            <source>Neurotoxicology</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1-2</issue>
            <fpage>243</fpage>
            <page-range>243-50</page-range>
            <pub-id pub-id-type="pmid">14697899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McCrodden</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Tipton</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>Monoamine oxidase inhibitors and the cheese effect.</article-title>
            <source>Neurochem Res</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>1145</fpage>
            <page-range>1145-9</page-range>
            <pub-id pub-id-type="pmid">8255365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Vashistha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Houchens</surname>
                <given-names>NW</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome: Preventing, recognizing, and treating it.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>83</volume>
            <issue>11</issue>
            <fpage>810</fpage>
            <page-range>810-817</page-range>
            <pub-id pub-id-type="pmid">27824534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyer</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The serotonin syndrome.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Mar</month>
            <day>17</day>
            <volume>352</volume>
            <issue>11</issue>
            <fpage>1112</fpage>
            <page-range>1112-20</page-range>
            <pub-id pub-id-type="pmid">15784664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haddad</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant discontinuation syndromes.</article-title>
            <source>Drug Saf</source>
            <year>2001</year>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-97</page-range>
            <pub-id pub-id-type="pmid">11347722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dilsaver</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Withdrawal phenomena associated with antidepressant and antipsychotic agents.</article-title>
            <source>Drug Saf</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-14</page-range>
            <pub-id pub-id-type="pmid">7912078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lippman</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Monoamine oxidase inhibitor update. Potential adverse food and drug interactions.</article-title>
            <source>Drug Saf</source>
            <year>1990</year>
            <season>May-Jun</season>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-204</page-range>
            <pub-id pub-id-type="pmid">2190595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schenk</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Remick</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Sublingual nifedipine in the treatment of hypertensive crisis associated with monoamine oxidase inhibitors.</article-title>
            <source>Ann Emerg Med</source>
            <year>1989</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>114</fpage>
            <page-range>114-5</page-range>
            <pub-id pub-id-type="pmid">2910154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.</article-title>
            <source>J Neural Transm (Vienna)</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>125</volume>
            <issue>11</issue>
            <fpage>1707</fpage>
            <page-range>1707-1717</page-range>
            <pub-id pub-id-type="pmid">30255284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laughren</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Levenson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hammad</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Temple</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rochester</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration.</article-title>
            <source>BMJ</source>
            <year>2009</year>
            <month>Aug</month>
            <day>11</day>
            <volume>339</volume>
            <fpage>b2880</fpage>
            <pub-id pub-id-type="pmid">19671933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fagerholm</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Haaparanta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scheinin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>&#x003b1;2-adrenoceptor regulation of blood glucose homeostasis.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>365</fpage>
            <page-range>365-70</page-range>
            <pub-id pub-id-type="pmid">21418144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mason</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Balcezak</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome. Presentation of 2 cases and review of the literature.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>201</fpage>
            <page-range>201-9</page-range>
            <pub-id pub-id-type="pmid">10941349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24736.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chobanian</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Izzo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Materson</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Roccella</surname>
                <given-names>EJ</given-names>
              </name>
              <collab>National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</collab>
              <collab>National High Blood Pressure Education Program Coordinating Committee</collab>
            </person-group>
            <article-title>The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.</article-title>
            <source>JAMA</source>
            <year>2003</year>
            <month>May</month>
            <day>21</day>
            <volume>289</volume>
            <issue>19</issue>
            <fpage>2560</fpage>
            <page-range>2560-72</page-range>
            <pub-id pub-id-type="pmid">12748199</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
